Management of IgG4-Related Disease (IgG4-RD)

1. When to Treat (and When to Watch)

• Disease is limited to lymphadenopathy (often asymptomatic for years)
• There is no vital organ involvement
• The patient has significant comorbidities that increase treatment risk

• End-stage liver disease (from sclerosing cholangitis)
• Permanent pancreatic insufficiency (exocrine and endocrine)
• Renal atrophy
• Aortic dissection or aneurysm
• Destructive lesions in sinuses and nasopharynx

Harrison's Principles of Internal Medicine, 22nd ed. (2025), p. 2976

2. First-Line Therapy: Glucocorticoids

Induction of Remission

• Prednisone (prednisolone) 40 mg/day (fixed dose), OR
• Weight-based dosing: 0.6-1 mg/kg/day (minimum 20 mg/day is generally required to induce remission)

Tapering

• High-dose steroids are rapidly tapered after response
• Two major strategies:
  • Short course: Taper to discontinuation or to a maintenance dose of ~5 mg/day within 2-3 months
  • Japanese/Asian guidelines approach: Continue high-dose for 3 months, then taper to a low dose (2.5-5 mg/day) for up to 3 additional years. An RCT by Masamune et al. showed 76.7% of patients on this low-dose maintenance strategy were in long-term remission.

Yamada's Textbook of Gastroenterology, 7th ed.; Harrison's, p. 2977

3. Maintenance Therapy

1. Remarkably high serum IgG4 levels before treatment
2. Persistently high serum IgG4 after steroid treatment
3. Diffuse pancreatic enlargement
4. Proximal-type IgG4-related sclerosing cholangitis (highest risk - can rapidly progress to cirrhosis)
5. More than two organs involved at presentation

• Low-dose steroids (2.5-5 mg/day) - best evidence, supported by RCT
• Azathioprine - steroid-sparing immunomodulator; experience is limited; does not appear to prolong relapse-free survival when added to steroids in most studies
• Calcineurin inhibitors - used in some non-salivary manifestations

Yamada's Textbook of Gastroenterology, 7th ed.; Harrison's Sclerosing Cholangitis chapter

4. Management of Relapse

Yamada's, Treatment of relapse section

5. Second-Line Therapy: Rituximab (Anti-CD20 B-cell Depletion)

• Leads to rapid decline in serum IgG4 concentrations (by depleting plasmablasts/short-lived plasma cells)
• More importantly, B-cell depletion modifies T-cell function - specifically targeting the CD4+ cytotoxic T cell that drives profibrotic cytokine production (IFN-γ, TGF-β, IL-1)
• Clinical trials (86% of patients with pancreaticobiliary IgG4-RD in complete or partial remission at 6 months) support its efficacy

• Relapsing disease
• Glucocorticoid-resistant disease
• Potentially first-line in patients at high risk for steroid toxicity (elderly, diabetic, osteoporotic, or patients with comorbidities)
• Phase 3 trials of CD19+ B-cell targeted therapies are at advanced stages and may expand options

Harrison's, p. 2977; Yamada's, relapse section

6. Adjuvant and Organ-Specific Management

7. Monitoring and Follow-Up

• Serum IgG4 is a useful, though imperfect, biomarker. Persistently elevated or rising IgG4 after treatment warrants reassessment. Note: ~30-40% of patients with active IgG4-RD have normal serum IgG4 levels (false-negative rate is significant).
• Imaging of affected organs to document response
• Watch for disease evolution to new organ sites, especially with rising IgG4
• Screen for malignancy in long-standing disease (lymphoma risk is slightly increased, though overall cancer risk does not appear significantly elevated above background)

8. Novel and Emerging Therapies

• Phase 3 clinical trials targeting CD19+ B lymphocytes are actively recruiting (as of 2025)
• Agents targeting the unique CD4+ cytotoxic T cell subset (which produces IFN-γ, TGF-β, IL-1) are under investigation
• B-cell-targeted strategies may become appropriate first-line options for organ-threatening disease or high glucocorticoid-risk patients once trial data mature

Harrison's, p. 2977

Summary Algorithm

Active IgG4-RD with organ involvement
        ↓
Is vital organ threatened? → Yes → Treat aggressively
        ↓ No
Watchful waiting vs. treat
        ↓
FIRST LINE: Prednisone 40 mg/day → taper over 2-3 months
        ↓
Assess response at 2-4 weeks (imaging, serum IgG4, symptoms)
        ↓
Remission achieved?
  ├── Yes → Maintenance therapy if high-relapse risk features
  └── No  → Rituximab (1g IV × 2 doses)
        ↓
Relapse?
  ├── Re-induction with steroids ± maintenance
  └── Rituximab (induction + maintenance every 2-3 months)

• Harrison's Principles of Internal Medicine, 22nd ed. (2025), Ch. 380
• Yamada's Textbook of Gastroenterology, 7th ed.
• Grainger & Allison's Diagnostic Radiology, 7th ed.
• Scott-Brown's Otorhinolaryngology Head & Neck Surgery
• Robbins & Cotran Pathologic Basis of Disease, 10th ed.